Chymotrypsin: A Comprehensive Encyclopedic Reference
1. Identity, Chemical Classification, and Natural Source
1.1 Names and Classification
Chymotrypsin (EC 3.4.21.1; chymotrypsins A and B; also known under trade and pharmaceutical designations including alpha-chymar ophth, avazyme, chymar, chymotest, enzeon, quimar, quimotrase, alpha-chymar, alpha-chymotrypsin A, and alpha-chymotrypsin) is a digestive enzyme component of pancreatic juice acting in the duodenum, where it performs proteolysis, the breakdown of proteins and polypeptides. Its CAS number is 9004-07-3. In vivo, chymotrypsin is a proteolytic enzyme (serine protease) acting in the digestive systems of many organisms.
1.2 Natural Source and Biological Origin
Chymotrypsin is a digestive enzyme that breaks down proteins (i.e., it is a proteolytic enzyme, also referred to as a protease). It is naturally produced by the pancreas in the human body. Chymotrypsin is a protein-digesting enzyme that is synthesized and secreted by the pancreatic acinar cells; it is produced by the action of trypsin on chymotrypsinogen. For commercial and supplement production, chymotrypsin is extracted from bovine (cattle) or porcine (pig) pancreatic tissue. The food enzyme is a serine protease complex containing trypsin (EC 3.4.21.4) and chymotrypsin (EC 3.4.21.1), obtained from porcine pancreas. Bovine pancreas is also a recognized source; alpha-chymotrypsin is described as a proteolytic enzyme extracted from bovine or porcine pancreas, presenting as a white or off-white crystalline powder.
1.3 Isoforms and Historical Identification
The scientific identification of chymotrypsin was not widely accepted until 1934, when Kunitz and Northrop confirmed the presence of an enzyme in addition to trypsin, naming it chymotrypsin and crystallizing both chymotrypsin and its inactive precursor chymotrypsinogen. In 1938, Kunitz isolated different active forms of chymotrypsin, designating them as alpha, beta, and gamma. Jacobsen later identified additional forms, designating them as delta and pi (Jacobsen, 1947). The most pharmacologically and commercially significant isoform is alpha-chymotrypsin (α-chymotrypsin).
1.4 Molecular Structure
α-Chymotrypsin is a serine peptidase containing 241 amino acid residues organized in three polypeptide chains (A chain: 13 residues, B chain: 131 residues, and C chain: 97 residues) linked by disulfide bridges. Its molecular weight is approximately 25 kDa and its isoelectric point (pI) is 8.75. α-Chymotrypsin from bovine pancreas selectively catalyzes the hydrolysis of peptide bonds on the C-terminal side of tyrosine, phenylalanine, tryptophan, and leucine. The pH optimum is approximately 7.88, with about 35% of maximal activity at pH 6.0 and 40% of maximal activity at pH 9.3, and the temperature optimum is 50°C.
1.5 Common Forms and Preparations
Chymotrypsin can be taken as an enzyme supplement to improve health and digestion and aid in the treatment of various diseases. A typical formulation may include: chymotrypsin (0.5–1 mg), bromelain (a plant protease) (25–45 mg), pancreatin (a mixture of many pancreatic enzymes) (100 mg), papain (a plant protease similar in action to chymotrypsin) (25–60 mg), and trypsin (a pancreatic protease) (24 mg). Formulations may also include vitamins, herbs, phytochemicals, and other nutrients to enhance enzyme activity.
Chymotrypsin appears in several pharmacological and supplemental forms:
- Oral tablets or enteric-coated tablets — the predominant form for systemic enzyme therapy, often combined with trypsin (e.g., the widely studied combination product "Chymoral Forte")
- Injectable solutions — used historically and in current ophthalmic and surgical contexts
- Inhalation preparations — used historically for respiratory conditions
- Topical preparations — applied to wounds and skin ulcers
Recognized guidelines for measuring enzyme activity include Food Chemicals Codex (FCC), United States Pharmacopoeia (USP), Federation Internationale du Pharmaceutiques (FIP), British Pharmacopoeia (BP), and Japanese Pharmacopoeia (JP). Activity is usually indicated in units; however, there is no single universal standard for enzyme activity level.
2. Traditional and Historical Use
2.1 Pre-Modern Use of Proteolytic Enzymes
Proteolytic enzymes have been used to facilitate tissue repair since ancient times. However, chymotrypsin as a specifically isolated and characterized enzyme is entirely a product of modern biochemistry; ancient and traditional cultures employed crude proteolytic preparations from animal or plant sources, not purified chymotrypsin. The concept that the pancreas generates intrinsic enzymatic activators was formally proposed as early as the turn of the twentieth century: in the early 1900s, Vernon proposed that pancreatic preparations could give rise to an intrinsic activator of its own enzymes (Vernon 1901).
2.2 Scientific Discovery and Early Medical Use (20th Century)
The scientific identification of chymotrypsin was not widely accepted until 1934, when Kunitz and Northrop confirmed the presence of an enzyme in addition to trypsin, naming it chymotrypsin and successfully crystallizing both it and its inactive precursor, chymotrypsinogen. In 1938, Kunitz isolated different active forms. In the early 1940s, Fruton and Bergmann further studied the specificity of chymotrypsin, reporting on several new substrates.
Trypsin:chymotrypsin is an oral proteolytic enzyme preparation which has been in clinical use since the 1960s. Its use in ophthalmology was particularly notable: Joaquin Barraquer is credited with the discovery of the practical use of α-chymotrypsin, a proteolytic enzyme, in facilitating cataract extraction, demonstrating both experimentally and clinically that the enzyme, marketed under the trade name of Quimotrase, possessed anti-inflammatory properties. This milestone occurred in 1958 and rapidly generated wide clinical interest. Since α-chymotrypsin was introduced by J. Barraquer in 1958, a number of reports appeared discussing the merits and demerits of the employment of this new agent in cataract surgery.
Contemporaneous with its ophthalmic introduction, chymotrypsin was explored as an oral and injectable anti-inflammatory agent. Chymotrypsins act primarily as an aid to digestion and as anti-inflammatory agents by preventing tissue damage and fibrin clots; consequently, they were used for treating bacterial, viral, fungal, and parasitic infections in mammals. By the 1960s and 1970s, combination oral enzyme preparations containing chymotrypsin and trypsin became commercially available in multiple countries, especially in Europe and Asia, and were used for post-surgical and post-traumatic inflammation management.
3. Key Constituents and Molecular Identity
3.1 Enzymatic Class
The reaction is facilitated by push–pull proton transfer involving specific imidazole, carboxyl, and hydroxyl groups that are common to hundreds of other mechanistically related enzymes in the "serine"-protease superfamily. Chymotrypsin belongs to the serine protease superfamily due to its use of a serine residue as the principal nucleophile in catalysis.
3.2 The Catalytic Triad
The active site of chymotrypsin contains the catalytic triad: aspartate, histidine, and serine. The three amino acid residues of the catalytic triad (H57, D102, and S195) are essential for peptide bond cleavage and are stabilized by hydrogen bonds. Chymotrypsin works primarily due to its hydrophobic pocket in the active site, which attracts substrates with hydrophobic regions in their molecular structure.
3.3 Substrate Specificity
Chymotrypsin preferentially cleaves peptide amide bonds where the side chain of the amino acid N-terminal to the scissile amide bond (the P1 position) is a large hydrophobic amino acid (tyrosine, tryptophan, and phenylalanine). These amino acids contain an aromatic ring in their side chain that fits into a hydrophobic pocket (the S1 position) of the enzyme. A secondary hydrolysis also occurs on the C-terminal side of methionine, isoleucine, serine, threonine, valine, histidine, glycine, and alanine.
3.4 Inhibitors and Stabilizers
Calcium ion (Ca2+) activates and stabilizes the enzyme. The enzyme is inhibited by diisopropyl fluorophosphate (DFP), phenylmethanesulfonyl fluoride (PMSF), N-p-tosyl-L-phenylalanine chloromethyl ketone (TPCK), chymostatin, aprotinin, α1-antitrypsin, and α2-macroglobulin, as well as 10 mM Cu2+ and Hg2+.
4. Mechanisms of Action
4.1 Digestive Mechanism
Chymotrypsin, as a hydrolase type of enzyme (which adds a water molecule during the breakdown process), acts by catalyzing the hydrolysis of peptide bonds of proteins in the small intestine. Chymotrypsin is secreted by the pancreas in an inactive form known as chymotrypsinogen, which is a zymogen. Upon the ingestion of food, chymotrypsinogen is activated through proteolytic cleavage, allowing chymotrypsin to begin its role in degrading dietary proteins.
The activation cascade is sequential: upon secretion into the lumen of the small intestine, chymotrypsinogen is converted to its active form by trypsin. Specifically, chymotrypsin is activated through cleavage of the bond between arginine and isoleucine (R15 and I16) by trypsin, causing structural modifications and formation of the substrate binding site.
4.2 Catalytic (Ping-Pong) Mechanism
Chymotrypsin operates through a general mechanism known as the ping-pong mechanism, whereby the enzyme reacts with a substrate to form an intermediate. More specifically, chymotrypsin operates through a particular type of ping-pong mechanism called covalent hydrolysis, meaning the enzyme first forms a covalent bond with the target substrate, displacing the more stable moiety into solution. Chymotrypsin cleaves peptide bonds by attacking the unreactive carbonyl group with a powerful nucleophile, the serine 195 residue located in the active site of the enzyme, which briefly becomes covalently bonded to the substrate, forming an enzyme-substrate intermediate.
4.3 Systemic Anti-inflammatory Mechanisms (Proposed)
Despite extensive evaluation, the mechanisms of beneficial effects associated with trypsin:chymotrypsin combination remain incompletely understood. Several postulated mechanisms have been described in the literature:
- In the course of the anti-inflammatory action, enzymes degrade damaged cells and necrotic material and, through the inactivation of mediators and toxic products, they restrict the edema and pain.
- Since the inflammatory process is thought to be due to peptides elaborated at the site of tissue trauma, it has been postulated that the increased blood esterase due to trypsin-chymotrypsin administration inhibits inflammation by hydrolytic degradation of the inflammatory peptides.
- Since α1-antitrypsin shows greater affinity for trypsin and chymotrypsin compared to plasmin, oral supplementation of the enzyme complex ensures that plasmin remains available for fibrinolysis.
- Steinhoff et al. described biological activity of trypsin and chymotrypsin on signal transduction cascades and production of second messengers leading to apoptosis, supporting host defense, regulating immune modulation, inflammation, and others.
It has also been demonstrated that subsequent cleavage of the propeptide by chymotrypsin C (CTRC) induces a nearly 10-fold increase in the activity of trypsin-activated carboxypeptidases CPA1 and CPA2, illustrating chymotrypsin's broader regulatory role in the digestive enzyme cascade.
4.4 Oral Absorption and Bioavailability
The question of whether orally administered chymotrypsin is absorbed intact and retains biological activity has been studied since at least the 1960s. When chymotrypsin was administered orally to 27 patients, a statistically significant increase in plasma chymotrypsin levels was found 4 hours after administration; this experiment was designed primarily to determine whether chymotrypsin was absorbed from the intestinal tract of man. Quantitative data necessary to speculate on the clinical significance of these findings were noted to be unavailable at that time.
More recent pharmacokinetic research has advanced this understanding: orally administered proteolytic enzymes can be detected transiently as intact, high-molecular-weight, physiologically active protein molecules, either free (in nanomolar concentrations) or in a complex with anti-proteases, in plasma, lymph, or injured tissue. Data from pharmacokinetic investigations reveal a dose-dependent linearity of maximum plasma levels, high inter-individual variability, plasma concentrations comparable to the body's own proteases, and an unusual invasion and elimination kinetic (slow velocity of absorption, fast and 100% protein binding to anti-proteases). So far, it can be concluded that proteolytic enzymes are absorbed as intact, high-molecular-weight molecules, retaining their activity as either free proteases or anti-protease bound complexes.
Trypsin:chymotrypsin shows high bioavailability without losing its biological activities as an anti-inflammatory, anti-edematous, fibrinolytic, antioxidant, and anti-infective agent. However, it should be noted that absolute bioavailability values and precise pharmacokinetic parameters for chymotrypsin as an isolated oral supplement in humans remain incompletely characterized in the published literature.
5. Body Systems and Areas of Health Association
5.1 Digestive System
Chymotrypsin is a digestive peptidase that hydrolyzes peptide bonds during protein breakdown, helping dietary proteins to be absorbed and allowing amino acids to be recycled. Each day the pancreas secretes about 1.5 quarts (1.4 liters) of pancreatic juice, consisting of enzymes, water, and electrolytes (primarily bicarbonate) into the small intestine. The enzymes are secreted in an inactive form (as proenzymes) so that they will not digest the pancreas.
5.2 Musculoskeletal and Trauma Systems
Chymotrypsin and trypsin:chymotrypsin combinations have been associated with the resolution of inflammation, edema, and pain following orthopedic injury and surgery. Owing to anti-inflammatory, anti-edematous, fibrinolytic, anti-infective, and analgesic effects, trypsin:chymotrypsin oral combination has emerged as a promising treatment to facilitate healing of traumatic injuries.
5.3 Ophthalmological System
Alpha-chymotrypsin has a direct clinical application in ophthalmic surgery, where it enzymatically dissolves the zonular fibers (zonulolysis) that hold the lens of the eye, thereby facilitating intracapsular cataract extraction.
5.4 Integumentary System (Skin and Wounds)
Chymotrypsin has been investigated for use in wound debridement and management of skin ulcers, burns, and abscesses through its proteolytic degradation of necrotic tissue.
5.5 Oral and Maxillofacial System
Because conventional anti-inflammatory medications (steroid and NSAIDs) are associated with several adverse effects, natural anti-inflammatory proteolytic enzymes, such as trypsin, chymotrypsin, papain, serratiopeptidase, and bromelain have been used following lower third molar surgery.
5.6 Salivary Gland System
There is some evidence that injecting chymotrypsin into the ducts of salivary (parotid) glands might decrease pain and swelling in people with chronic obstructive parotitis.
6. Scientific Evidence by Area of Use
6.1 Post-Surgical and Post-Traumatic Edema and Inflammation
Evidence strength: Moderate; multiple randomized and controlled clinical trials, though many are older, have small sample sizes, or involve co-administered agents.
Pages conducted a clinical trial to investigate the efficacy, safety, and tolerability of trypsin:chymotrypsin (Chymoral Mauchant) treatment to resolve edema and hemorrhagic infiltration due to tissue trauma in orthopedic surgery patients. Chymoral Mauchant contains 50,000 Armour units of trypsin and chymotrypsin, and in an adult of average body weight, 6–8 tablets daily were given.
In a randomized clinical trial at Grant Medical College, Mumbai, India, three oral enzyme treatment groups were compared: oral tablets containing trypsin:chymotrypsin (TC) (Chymoral Forte®), serratiopeptidase (S) 5 mg oral tablets, and oral enzyme tablets containing trypsin 48 mg, bromelain 90 mg, and rutoside 100 mg (TBR), to evaluate their healing potential in surgical wounds after orthopedic surgery. A total of 75 patients were screened, randomized, and divided into three groups in a 1:1:1 ratio. TC provided better resolution of symptoms of inflammation after orthopedic surgery as compared to serratiopeptidase and TBR, thus facilitating better wound healing; global assessment of response to therapy for efficacy and tolerability was reported to be good to excellent.
The efficacy and safety of trypsin:chymotrypsin in accidental injuries, surgical and orthopedic injuries, burns, and sciatica has been corroborated by a substantial and largely consistent body of evidence from clinical trials. The PMC review article (2018) noted, however, that article publication charges were funded by Torrent Pharmaceuticals Limited, representing an acknowledged potential conflict of interest that limits conclusions.
6.2 Third Molar (Wisdom Tooth) Surgery
Evidence strength: Moderate; prospective, randomized, controlled trials exist, though sample sizes are generally small.
Several randomized clinical trials have reported beneficial effects of proteolytic enzymes in reducing postoperative complications following third molar surgery. A prospective, randomized, double-blind, controlled clinical trial published in Frontiers in Oral Health (2020) evaluated the efficacy of submucosal injection of chymotrypsin versus oral serratiopeptidase or oral dexamethasone in reducing postoperative complications following impacted lower third molar surgery. Chymotrypsin and trypsin, bromelain (pineapple enzyme), and papain are proteolytic enzymes that have been taken to decrease inflammation, reduce edema, and accelerate healing.
6.3 Endodontic (Root Canal) Postoperative Pain
Evidence strength: Preliminary; one small randomized controlled trial.
A prospective, parallel, triple-blinded phase IV randomized controlled trial included 60 patients with mandibular first molars exhibiting symptomatic irreversible pulpitis. Patients were randomly allocated to one of four treatment groups (n=15 each) and were administered either ibuprofen (600 mg), ambezim-G (trypsin 5 mg–chymotrypsin 5 mg), a combination of both, or placebo postoperatively. The study found that trypsin-chymotrypsin exhibits comparable efficacy to nonsteroidal anti-inflammatory drugs. The small sample size (n=15 per group) severely limits the generalizability of these findings.
6.4 Pain Management Compared to NSAIDs
Evidence strength: Preliminary to moderate; multiple small trials with mixed comparators.
At 6 hours postoperatively in one trial, mean pain scores were 4.31 (ibuprofen), 3.85 (trypsin–chymotrypsin), and 4.23 (serratiopeptidase) (P = 0.823). Trypsin–chymotrypsin and serratiopeptidase demonstrated statistically comparable postoperative pain reduction to ibuprofen. Both agents exhibited comparable efficacy to NSAIDs. Application of trypsin–chymotrypsin or serratiopeptidase was well tolerated, with no adverse events noted. These findings, while promising, require larger and more rigorously blinded trials for confirmation.
6.5 Burns
Evidence strength: Weak; limited clinical data, some evidence of cytokine modulation.
There is some evidence that taking a mixture of chymotrypsin and trypsin by mouth might decrease tissue destruction in burn patients. Research referenced in clinical trial literature includes studies evaluating serum enzymatic changes and cytokine levels in burn patients receiving trypsin:chymotrypsin preparations (Latha B, Ramakrishnan M, et al., Burns, 1998; RaviKumar T, et al., Burns, 2001). The overall evidence base for this indication is limited and requires larger, well-controlled trials.
6.6 Fractures
Evidence strength: Weak to preliminary; limited clinical data.
There is some evidence that taking a mixture of chymotrypsin and trypsin by mouth might reduce swelling in hand fractures. This evidence is based on a small number of older clinical reports and is insufficient to draw firm conclusions.
6.7 Chronic Obstructive Parotitis
Evidence strength: Preliminary; limited to one or a few clinical studies.
There is some evidence that injecting chymotrypsin into the channels (ducts) in salivary (parotid) glands might decrease pain and swelling in people with chronic obstructive parotitis. A study by Sun HJ et al. (Int J Oral Maxillofac Surg, 2017) investigated chymotrypsin with sialendoscopy-assisted surgery for the treatment of this condition, though this represents limited and early-stage evidence.
6.8 Cataract Surgery (Ophthalmological Use)
Evidence strength: Well-established in historical clinical practice, though mostly replaced by modern phacoemulsification techniques; use now primarily of historical interest.
Joaquin Barraquer is credited with the discovery of the practical use of α-chymotrypsin in facilitating cataract extraction, demonstrating both experimentally and clinically that the enzyme, marketed under the trade name of Quimotrase, could aid in intracapsular lens extraction. A substantial body of case series and controlled studies from the 1958–1970 era documented its use. By dissolving zonular fibers (enzymatic zonulolysis), alpha-chymotrypsin permitted safer intracapsular lens extraction. With the advent of modern phacoemulsification extracapsular cataract surgery, this indication has become largely obsolete in contemporary practice.
6.9 Areas with Insufficient Evidence
Additional conditions for which chymotrypsin has been studied or proposed include swelling of the main airways in the lung (bronchitis), critical illness (trauma), sinus infections, skin conditions such as abscesses and ulcers, and wound healing. More evidence is needed to rate the effectiveness of chymotrypsin for these uses.
7. Dosage Forms and Reported Dosages
Reported dosages from the scientific literature and authoritative references vary by route of administration and indication. The following are drawn directly from cited sources and should not be interpreted as prescriptive guidance:
- Oral combination (trypsin:chymotrypsin) for burn injury: A 6:1 ratio (trypsin:chymotrypsin), in a combined amount of 200,000 units USP four times daily for ten days has been reported.
- Oral combination for orthopedic surgery: Pages' clinical trial used Chymoral Mauchant, containing 50,000 Armour units of trypsin and chymotrypsin, with an adult of average body weight receiving 6–8 tablets daily.
- Oral combination for endodontic postoperative pain: In a randomized controlled trial, ambezim-G (trypsin 5 mg – chymotrypsin 5 mg) was administered postoperatively.
- Oral combination therapy: general enzyme therapy formulation: Medications were started 24 hours after surgery, three times a day for 7–10 days in some orthopedic surgical studies.
- Intracameral injection (ophthalmic): All dogs in one veterinary study underwent bilateral intracapsular lens extraction 7 minutes following injection of 75 U of α-chymotrypsin into the posterior chamber of the eye. (This study was conducted in animals, not humans, and is cited as a reference point for dose ranges only.)
- Supplement combination tablet (typical formulation): A typical formulation may include chymotrypsin 0.5–1 mg combined with bromelain (25–45 mg), pancreatin (100 mg), papain (25–60 mg), and trypsin (24 mg).
When taken by mouth, chymotrypsin is described as possibly safe for most people when mixed with trypsin and used short-term, with doses up to 800,000 units per day of this combination documented in the literature.
8. Safety Considerations and Interactions
8.1 General Safety Profile
In the toxicological evaluation conducted by EFSA, clinical studies with pharmaceutical preparations containing pancreatic enzymes were considered. Hypersensitivity to the pharmaceuticals was identified as the major side effect. However, allergic reactions to porcine pancreatic enzymes in hydrolysed foods have not been reported.
Proteins from pig pancreas are oral allergens, as evidenced by pharmaceutical use, but they are not known to be food allergens. Foods in which the enzyme has been applied have been on the market with only rare reports of adverse allergic reactions in infants; the specificity of these adverse reactions has not been established.
8.2 Adverse Effects by Route of Administration
Ophthalmic use: Chymotrypsin can cause side effects when used in the eye, including an increase in pressure in the eye and other eye conditions.
Oral use: Application of trypsin–chymotrypsin was well tolerated, with no adverse events noted in one randomized clinical trial. The EFSA panel's review of toxicological data from pharmaceutical preparations identified hypersensitivity as the primary concern.
Injectable use: Injection-site reactions (swelling, local inflammation) and, in rare cases, more systemic responses are possible, as noted in the literature on pharmaceutical protease preparations. Due to its fibrinolytic activity, alpha-chymotrypsin should be applied only for postoperative edema and hematoma prophylaxis even at doses of 5 and 10 mg (as indicated in the List of Drugs), with due regard to the simultaneous effect on hemostasis. The maximum of fibrinolytic activity was observed 6 to 9 hours after intramuscular injection. The authors dissuade from uncontrolled use because, in spite of many separate experimental studies and clinical trials, there are still numerous questions that must be considered unsettled.
8.3 Allergenicity and Hypersensitivity
In EFSA's toxicological evaluation, clinical studies with pharmaceutical preparations containing pancreatic enzymes were considered, and hypersensitivity to the pharmaceuticals was identified as the major side effect. The enzyme is derived from mammalian (bovine or porcine) pancreatic tissue, which carries inherent allergenicity potential for individuals sensitized to porcine or bovine proteins. Occupational sensitization from inhalation of pancreatic enzyme dusts has also been documented in industrial and pharmaceutical manufacturing contexts.
8.4 Fibrinolytic and Hemostatic Considerations
Since α1-antitrypsin shows greater affinity for trypsin and chymotrypsin compared to plasmin, oral supplementation of the enzyme complex ensures that plasmin remains available for fibrinolysis, which has theoretical implications for individuals with coagulation disorders or those taking anticoagulant medications. The fibrinolytic activity of alpha-chymotrypsin, as noted above from PubMed-indexed literature, is a recognized pharmacological consideration when this agent is used in contexts involving hemostasis.
8.5 EFSA Regulatory Evaluations
The European Food Safety Authority has conducted multiple formal safety evaluations of food enzymes containing chymotrypsin:
- The EFSA CEP Panel published a scientific opinion on the safety evaluation of a food enzyme containing trypsin, chymotrypsin, elastase, and carboxypeptidase from porcine pancreas (EFSA Journal 2021;19(1):6368).
- A separate EFSA evaluation covered a serine protease complex containing trypsin and chymotrypsin from porcine pancreas, intended for hydrolysis of whey proteins in infant formulae and follow-on formulae, with estimated dietary exposure of 18 mg TOS/kg body weight per day for infants.
8.6 Notable Precautions from Regulatory and Clinical Sources
- An allergic reaction upon oral ingestion of pancreatin in individuals respiratory-sensitized to the food enzyme cannot be ruled out, but the likelihood of such a reaction is considered to be low.
- Chymotrypsin's fibrinolytic and anti-hemostatic properties, established in the pharmacological literature, warrant caution in peri-operative contexts and in individuals with bleeding disorders.
- The source of commercial chymotrypsin (bovine or porcine pancreas) is relevant for individuals with religious or ethical restrictions on such animal-derived products.
- In spite of many separate experimental studies and clinical trials, there are still numerous questions [regarding use] that must be considered unsettled, highlighting the need for continued rigorous investigation.
9. Evidence Summary and Research Limitations
The overall body of clinical evidence for chymotrypsin as a supplement or therapeutic agent in anti-inflammatory and anti-edematous indications is positive in direction but limited in methodological rigor. Trypsin:chymotrypsin promotes speedier recovery and better resolution of inflammatory signs and symptoms due to tissue injury than several other existing enzyme preparations. It also demonstrates analgesic effects and reduces pain associated with healing. However, most trials are small in size, originate from a limited number of research groups, and in some cases are funded by manufacturers.
For its well-established digestive role, the biochemical and physiological evidence is extensive and unambiguous. For systemic anti-inflammatory uses, evidence from human clinical trials is accumulating but not yet at the level required for definitive recommendations by major regulatory bodies. The ophthalmological use in enzymatic zonulolysis is historically well-documented but now largely superseded by modern surgical techniques.
Key research gaps include: large, multicenter, placebo-controlled trials with standardized dosing and outcome measures; detailed pharmacokinetic studies of oral chymotrypsin in humans; clear elucidation of systemic mechanisms of action beyond in vitro and animal data; and long-term safety data for extended oral supplementation.
References
Go back